PLATFORM TECHNOLOGY
PIPELINE current situation
Below is a representation pipeline of PLABiologics' current stem cell therapy development based on PLAB's innovations.
| Project | Indication | Status | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
Indication Polycystic ovary syndrome |
Status preclinical |
preclinical GLP-Tox P1 P1/P2 |
|||||
Indication Macular degeneration |
Status preclinical |
preclinical GLP-Tox P1 |
|||||
Indication Metabolic dysfunction-associated steatohepatitis |
Status preclinical |
preclinical GLP-Tox P1 |
|||||
Indication Diabetic retinopathy |
Status preclinical |
preclinical GLP-Tox P1 |
|||||
UNIPla®
High-purity placental chorionic
plate-derived mesenchymal
stem cells
isolation and culture technology.
- The earliest stage of MSCs
- High-purity isolation quickly and easily without mixing of other cells
- Superior proliferative potentials as the earliest stage of MSCs
- No ethical problem.
- Multi-lineage differentiation potentials
- Accessibility to obtain of abundant stem cells.
- Immunosuppressive function
SUNIPla®
Functional enhancement stem
cells production technology.
- Safety with non-chromosomal insertion.
- High efficiency of gene introduction.
- stable cell line
- Easy and simple operation.
- Clear mode of action (MoA).
